{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:18:07Z","timestamp":1787962687355,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03913-z","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:20:23Z","timestamp":1745997623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vedolizumab\u2013steroid combination therapy improves long-term prognosis in patients with ulcerative colitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yosuke","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashiro","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshisuke","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"3913_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.dld.2011.10.004","volume":"44","author":"E Garcia-Planella","year":"2012","unstructured":"Garcia-Planella E, Ma\u00f1osa M, Van Domselaar M, Gordillo J, Zabana Y, Cabr\u00e9 E, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012;44:206\u201310.","journal-title":"Dig Liver Dis"},{"key":"3913_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041\u20138.","journal-title":"Br Med J"},{"key":"3913_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/apt.12834","volume":"40","author":"NH Khan","year":"2014","unstructured":"Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease-a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374\u201381.","journal-title":"Aliment Pharmacol Ther"},{"key":"3913_CR4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3390\/jcm11061679","volume":"11","author":"E De Cristofaro","year":"2022","unstructured":"De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, et al. Long-term risk of colectomy in patients with severe ulcerative colitis responding to intravenous corticosteroids or Infliximab. J Clin Med. 2022;11:1679.","journal-title":"J Clin Med"},{"key":"3913_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-2004-823066","volume":"17","author":"U Mahadevan","year":"2004","unstructured":"Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17:7\u201319.","journal-title":"Clin Colon Rectal Surg"},{"key":"3913_CR6","first-page":"e37609","volume":"15","author":"H Awan","year":"2023","unstructured":"Awan H, Fatima U, Eaw R, Knox N, Alrubaiy L. The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review. Cureus. 2023;15:e37609.","journal-title":"Cureus"},{"key":"3913_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/2040622315586970","volume":"6","author":"LN Cherry","year":"2015","unstructured":"Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an \u03914\u03b27 integrin antagonist for ulcerative colitis and Crohn\u2019s disease. Ther Adv Chronic Dis. 2015;6:224\u201333.","journal-title":"Ther Adv Chronic Dis"},{"key":"3913_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"3913_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, T\u00f6r\u00fcner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215\u201326.","journal-title":"N Engl J Med"},{"key":"3913_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649\u201370.","journal-title":"J Crohns Colitis"},{"key":"3913_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","volume":"298","author":"D Rachmilewitz","year":"1989","unstructured":"Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82\u20136.","journal-title":"BMJ"},{"key":"3913_CR12","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"3913_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3913_CR14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/apt.16060","volume":"52","author":"EV Loftus Jr","year":"2020","unstructured":"Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of Vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1353\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"3913_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/ibd\/izy384","volume":"25","author":"BE Sands","year":"2019","unstructured":"Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in combination with corticosteroids for induction therapy in Crohn\u2019s disease: a post hoc analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019;25:1375\u201382.","journal-title":"Inflamm Bowel Dis"},{"key":"3913_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3164\/jcbn.21-98","volume":"70","author":"N Yamashita","year":"2022","unstructured":"Yamashita N, Imai T, Kawahara M, Inatomi O, Andoh A. Low immunogenicity of Vedolizumab determined by a simple drug-tolerant assay in patients with ulcerative colitis. J Clin Biochem Nutr. 2022;70:72\u20138.","journal-title":"J Clin Biochem Nutr"},{"key":"3913_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12876-015-0333-z","volume":"15","author":"R Iwasa","year":"2015","unstructured":"Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y. C-reactive protein level at 2 weeks following initiation of Infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol. 2015;15:103.","journal-title":"BMC Gastroenterol"},{"key":"3913_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3109\/00365521.2016.1144781","volume":"51","author":"Y Morita","year":"2016","unstructured":"Morita Y, Bamba S, Takahashi K, Imaeda H, Nishida A, Inatomi O, et al. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-\u03b1 antibodies in ulcerative colitis. Scand J Gastroenterol. 2016;51:934\u201341.","journal-title":"Scand J Gastroenterol"},{"key":"3913_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/ecco-jcc\/jjz031","volume":"13","author":"S Hanauer","year":"2019","unstructured":"Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, et al. Rapid changes in laboratory parameters and early response to adalimumab: a pooled analysis from patients with ulcerative colitis in two clinical trials. J Crohns Colitis. 2019;13:1227\u201333.","journal-title":"J Crohns Colitis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03913-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03913-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03913-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:20:24Z","timestamp":1745997624000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03913-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3913"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03913-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of the Seirei Hamamatsu General Hospital (approval number 3932). This study was conducted in accordance with the principles of Good Clinical Practice and in adherence to the Declaration of Helsinki. Informed consent was obtained through an opt-out method, and the study details were posted on the hospital website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}